Cargando…
Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis
INTRODUCTION: The introduction of tumor necrosis factor-alpha (TNF-α) antagonists has substantially improved patient’s clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond to anti-TNF-α treatment strategies. To identify valid predictors of TNF-α ant...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383078/ https://www.ncbi.nlm.nih.gov/pubmed/25884688 http://dx.doi.org/10.1186/s13075-015-0553-1 |
_version_ | 1782364675942383616 |
---|---|
author | Blaschke, Sabine Rinke, Kathinka Maring, Michael Flad, Thomas Patschan, Susann Jahn, Olaf Mueller, Claudia A Mueller, Gerhard A Dihazi, Hassan |
author_facet | Blaschke, Sabine Rinke, Kathinka Maring, Michael Flad, Thomas Patschan, Susann Jahn, Olaf Mueller, Claudia A Mueller, Gerhard A Dihazi, Hassan |
author_sort | Blaschke, Sabine |
collection | PubMed |
description | INTRODUCTION: The introduction of tumor necrosis factor-alpha (TNF-α) antagonists has substantially improved patient’s clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond to anti-TNF-α treatment strategies. To identify valid predictors of TNF-α antagonist response in RA, serum proteome profiles from responders (R) and non-responders (NR) to etanercept, a soluble recombinant TNF-α receptor/IgG Fc fusion protein receptor, were compared in a prospective cohort study. METHODS: In this clinical study 50 RA patients with inadequate response to conventional DMARDs were included and treated with etanercept. The primary efficacy endpoint was response according to the European League against Rheumatism (EULAR) improvement criteria. Serum samples collected prior to initiation and after six months of etanercept therapy were cleared of the most abundant major proteins by immunoaffinity chromatography. After separation by two-dimensional differential gel electrophoresis (2D-DIGE) and identification by mass spectrometry (MS) data were validated by Western blot analysis. RESULTS: After six months of etanercept treatment 62% (n = 31) of RA patients achieved response. Haptoglobin-α1 (Hp-α1) and -α2 (Hp-α2) and vitamin D-binding protein (VDBP) were found to be significantly upregulated in responder sera (P ≤0.02) at study entry. In contrast, apolipoprotein C-III (ApoC-III) showed significantly higher levels in non-responders (P = 0.0162). At study end ApoA-II, Hp-α1, Hp-α2 and VDBP were identified to be expressed at significantly higher levels (P <0.05) in responder sera. CONCLUSIONS: By application of clinical proteomics in immunodepleted sera we could identify and validate for the first time Hp-α1, -α2, VDBP and ApoC-III as potential biomarkers for prediction of etanercept drug response in RA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0553-1) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4383078 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-43830782015-04-03 Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis Blaschke, Sabine Rinke, Kathinka Maring, Michael Flad, Thomas Patschan, Susann Jahn, Olaf Mueller, Claudia A Mueller, Gerhard A Dihazi, Hassan Arthritis Res Ther Research Article INTRODUCTION: The introduction of tumor necrosis factor-alpha (TNF-α) antagonists has substantially improved patient’s clinical outcome in rheumatoid arthritis (RA). However, nearly 20% to 40% of RA patients do not respond to anti-TNF-α treatment strategies. To identify valid predictors of TNF-α antagonist response in RA, serum proteome profiles from responders (R) and non-responders (NR) to etanercept, a soluble recombinant TNF-α receptor/IgG Fc fusion protein receptor, were compared in a prospective cohort study. METHODS: In this clinical study 50 RA patients with inadequate response to conventional DMARDs were included and treated with etanercept. The primary efficacy endpoint was response according to the European League against Rheumatism (EULAR) improvement criteria. Serum samples collected prior to initiation and after six months of etanercept therapy were cleared of the most abundant major proteins by immunoaffinity chromatography. After separation by two-dimensional differential gel electrophoresis (2D-DIGE) and identification by mass spectrometry (MS) data were validated by Western blot analysis. RESULTS: After six months of etanercept treatment 62% (n = 31) of RA patients achieved response. Haptoglobin-α1 (Hp-α1) and -α2 (Hp-α2) and vitamin D-binding protein (VDBP) were found to be significantly upregulated in responder sera (P ≤0.02) at study entry. In contrast, apolipoprotein C-III (ApoC-III) showed significantly higher levels in non-responders (P = 0.0162). At study end ApoA-II, Hp-α1, Hp-α2 and VDBP were identified to be expressed at significantly higher levels (P <0.05) in responder sera. CONCLUSIONS: By application of clinical proteomics in immunodepleted sera we could identify and validate for the first time Hp-α1, -α2, VDBP and ApoC-III as potential biomarkers for prediction of etanercept drug response in RA. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13075-015-0553-1) contains supplementary material, which is available to authorized users. BioMed Central 2015-03-06 2015 /pmc/articles/PMC4383078/ /pubmed/25884688 http://dx.doi.org/10.1186/s13075-015-0553-1 Text en © Blaschke et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Blaschke, Sabine Rinke, Kathinka Maring, Michael Flad, Thomas Patschan, Susann Jahn, Olaf Mueller, Claudia A Mueller, Gerhard A Dihazi, Hassan Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
title | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
title_full | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
title_fullStr | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
title_full_unstemmed | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
title_short | Haptoglobin-α1, -α2, vitamin D-binding protein and apolipoprotein C-III as predictors of etanercept drug response in rheumatoid arthritis |
title_sort | haptoglobin-α1, -α2, vitamin d-binding protein and apolipoprotein c-iii as predictors of etanercept drug response in rheumatoid arthritis |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4383078/ https://www.ncbi.nlm.nih.gov/pubmed/25884688 http://dx.doi.org/10.1186/s13075-015-0553-1 |
work_keys_str_mv | AT blaschkesabine haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis AT rinkekathinka haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis AT maringmichael haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis AT fladthomas haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis AT patschansusann haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis AT jahnolaf haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis AT muellerclaudiaa haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis AT muellergerharda haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis AT dihazihassan haptoglobina1a2vitamindbindingproteinandapolipoproteinciiiaspredictorsofetanerceptdrugresponseinrheumatoidarthritis |